In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 Christopher Paul Cannon
Speaker
Christopher Paul Cannon
Christopher Paul Cannon Christopher Paul Cannon

Brigham and Women s Hospital, Boston (United States of America)

Specialities : Risk Factors and Prevention , Acute Coronary Syndromes, Pharmacology and Pharmacotherapy, Risk Factors and Prevention

Christopher P. Cannon, MD Cardiovascular Innovation, Brigham and Women’s Hospital Professor of Medicine, Harvard Medical School, Boston, MA Dr. Cannon is a Professor of Medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He currently serves as Education Director in the Cardiovascular Innovation group. He has worked for 25 years as an investigator in the TIMI Study Group. He has been principal investigator of more than 20 multicenter clinical trials, including TACTICS-TIMI 18, PROVE IT, IMPROVE IT, and RE-DUAL PCI trials. In his role at Cardiovascular Innovation, he is helping implement quality improvement program 'Remote Health' for lipids and hypertension.

42 presentations from this speaker

Triple therapy is still needed in patients with atrial fibrillation undergoing PCI - CON.

Event : ESC Congress 2020

  • Session : Controversies in Antithrombotic Therapy: Is Triple Therapy Still Needed in Patients with Atrial Fibrillation Undergoing PCI?
  • Speaker : C Cannon (Boston,US)

Antithrombotic therapy in atrial fibrillation patients post-PCI: guidance from both sides of the Atlantic

Event : ESC Congress 2019

  • Session : Antithrombotic therapy in atrial fibrillation patients post-percutaneous coronary intervention: guidance from both sides of the Atlantic
  • Speaker : C Cannon (Boston,US), GYH Lip (Liverpool,GB)
  • Sponsored by Boehringer Ingelheim

Changing clinical outcomes with more intensive platelet inhibition

Event : ESC Congress 2019

  • Session : Intensive platelet inhibition in acute coronary syndromes - Where are we a decade after PLATO study results? (EBAC Accredited)
  • Speaker : C Cannon (Boston,US)
  • Supported by an unrestricted educational grant from AstraZeneca

Early administration of lipid lowering agents in acute coronary syndromes.

Event : ESC Congress 2019

  • Session : Cardiovascular drugs in acute coronary syndromes: when to start and when to stop
  • Speaker : C Cannon (Boston,US)

From RE-LY to RE-DUAL PCI: a decade of innovation

Event : ESC Congress 2019

  • Session : NOACs in patients undergoing cardiac procedures
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Intensive platelet inhibition - Have we reached the ceiling or are there options for further development?

Event : ESC Congress 2019

  • Session : Intensive platelet inhibition in acute coronary syndromes - Where are we a decade after PLATO study results? (EBAC Accredited)
  • Speaker : L Wallentin (Uppsala,SE), R Mehran (New York,US), RF Storey (Sheffield,GB), C Cannon (Boston,US), S James (Uppsala,SE)
  • Supported by an unrestricted educational grant from AstraZeneca

Lipids – Towards new guidelines based on recent trials?

Event : ESC Congress 2019

  • Session : The European Heart Journal’s advances from prevention to intervention: the year in Cardiology
  • Speaker : C Cannon (Boston,US)
  • Joint with the European Heart Journal

Panel discussion and questions and answers: NOACs in cardiac patients undergoing procedures

Event : ESC Congress 2019

  • Session : NOACs in patients undergoing cardiac procedures
  • Speaker : C Cannon (Boston,US), DJ Angiolillo (Jacksonville,US)
  • Sponsored by Boehringer Ingelheim

Antithrombotic therapy in patients with atrial fibrillation undergoing PCI – Represented in NEJM by the PIONEER-AF PCI trial and the RE-DUAL PCI trial

Event : ESC Congress 2018

  • Session : Highlights from the New England Journal of Medicine: Editors’ Choice
  • Speaker : C Cannon (Boston,US)
  • Organised with the New England Journal of Medicine

Bringing order to complexity: antithrombotic regimens for atrial fibrillation patients who underwent PCI.

Event : ESC Congress 2018

  • Session : Bringing order to complexity: antithrombotic regimens for atrial fibrillation patients who underwent percutaneous coronary intervention
  • Speaker : C Cannon (Boston,US), J ten Berg (Nieuwegein,NL)
  • Sponsored by Boehringer Ingelheim

Discussant review - The effect of randomization to omega-3 fatty acids in ASCEND.

Event : ESC Congress 2018

  • Session : Hot Line Session 2
  • Speaker : C Cannon (Boston,US)

Dual vs triple therapy in atrial fibrillation post-PCI: how has the story evolved?

Event : ESC Congress 2018

  • Session : Translating trials to clinical practice: is dual therapy the new standard of care for atrial fibrillation patients post-PCI?
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Improving care decisions in patients with atrial fibrillation: panel discussion and Q&A.

Event : ESC Congress 2018

  • Session : Translating trials to clinical practice: is dual therapy the new standard of care for atrial fibrillation patients post-PCI?
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Learnings from the latest PCSK9i results and profiles of patients who may benefit the most: a comprehensive review of the latest lipid lowering therapies outcomes data

Event : ESC Congress 2018

  • Session : Identifying patients who may benefit most from PCSK9i: highlights from the latest ODYSSEY OUTCOMES data
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Sanofi and Regeneron

Prevention in 2018 - Lipids.

Event : ESC Congress 2018

  • Session : The European Heart Journal’s advances from prevention to intervention: the year in Cardiology
  • Speaker : C Cannon (Boston,US)
  • Joint with the European Heart Journal

Wrap-up.

Event : ESC Congress 2018

  • Session : ESC ATLAS of Cardiology: statistics on cardiovascular disease and care
  • Speaker : C Cannon (Boston,US), TF Luscher (London,GB)

Antithrombotic strategies post-PCI in atrial fibrillation: new insights, new approach.

Event : ESC Congress 2017

  • Session : Antithrombotic strategies post-PCI in atrial fibrillation: new insights, new approach
  • Speaker : C Cannon (Boston,US), G Nickenig (Bonn,DE)
  • Sponsored by Boehringer Ingelheim

Dual vs triple antithrombotic therapy: new evidence.

Event : ESC Congress 2017

  • Session : RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Identifying appropriate patients to treat: a case-based approach.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : C Cannon (Boston,US), A Catapano (Milan,IT), SJ Nicholls (Adelaide,AU), PM Ridker (Boston,US), J Robinson (Iowa,US)
  • Sponsored by Sanofi and Regeneron

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Sanofi and Regeneron

Introduction - PSCK9 inhibition: a new horizon in LDL-C management.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : A Catapano (Milan,IT), J Robinson (Iowa,US), C Cannon (Boston,US)
  • Sponsored by Sanofi and Regeneron

Panel discussion - PSCK9 inhibition: a new horizon in LDL-C management.

Event : ESC Congress 2017

  • Session : PSCK9 inhibition: a new horizon in LDL-C management
  • Speaker : C Cannon (Boston,US), A Catapano (Milan,IT), J Robinson (Iowa,US)
  • Sponsored by Sanofi and Regeneron

Panel discussion Q&A - RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation.

Event : ESC Congress 2017

  • Session : RE-DUAL PCI and reversal: improving care decisions after coronary revascularisation
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Prevention in 2017 - An update

Event : ESC Congress 2017

  • Session : The European Heart Journal's Year in Cardiology: from prevention to intervention
  • Speaker : C Cannon (Boston,US)
  • Joint with the European Heart Journal

Antithrombotic strategies post-STEMI in AF patients.

Event : ESC Congress 2016

  • Session : Antithrombotic strategies post-STEMI in AF patients
  • Speaker : C Cannon (Boston,US), G Nickenig (Bonn,DE)
  • Sponsored by Boehringer Ingelheim

Prevention in 2016 - An update

Event : ESC Congress 2016

  • Session : The European Heart Journal's Year in Cardiology: from prevention to intervention
  • Speaker : C Cannon (Boston,US)
  • Joint with the European Heart Journal

The future is now.

Event : ESC Congress 2016

  • Session : The future is now: impact of oral anticoagulation reversal on your practice
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Closing - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion.

Event : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : C Cannon (Boston,US), U Laufs (Leipzig,DE)
  • Sponsored by MSD

IMPROVE-IT: where is the ground in aggressive LDL lowering after ACS?

Event : ESC Congress 2015

  • Session : Treatment of coronary artery disease: from recent clinical trials to practice
  • Speaker : C Cannon (Boston,US)

Opening by the chairs - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion.

Event : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : C Cannon (Boston,US), U Laufs (Leipzig,DE)
  • Sponsored by MSD

Panel discussion & Q&A - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion.

Event : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : C Cannon (Boston,US), U Laufs (Leipzig,DE), BA Ference (Cambridge,GB), AK Gitt (Ludwigshafen,DE), P Toth (Sterling,US)
  • Sponsored by MSD

Reaching new levels of low LDL-C: where is the limit?

Event : ESC Congress 2015

  • Session : Low Density Lipoprotein-Cholesterol (LDL-C) management - Can we redefine what is possible?
  • Speaker : C Cannon (Boston,US)
  • Sponsored by SANOFI and REGENERON

Should the same rules apply for drug and device approval? US - Physicians.

Event : ESC Congress 2015

  • Session : Should the same rules apply for drug and device approval? EU vs. US perspective
  • Speaker : C Cannon (Boston,US)

Treat to target or reaching new lower levels of LDL-C - Which approach for which patient.

Event : ESC Congress 2015

  • Session : Low Density Lipoprotein-Cholesterol (LDL-C) management - Can we redefine what is possible?
  • Speaker : C Cannon (Boston,US)
  • Sponsored by SANOFI and REGENERON

What do clinical outcome trials tell us? Lessons learned from IMPROVE-IT.

Event : ESC Congress 2015

  • Session : What do clinical outcome trials tell us?
  • Speaker : C Cannon (Boston,US)
  • Sponsored by MSD

What do recent trial results add to the legacy of lowering LDL cholesterol? Putting recent clinical study results in the context of pervious trials.

Event : ESC Congress 2015

  • Session : Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based discussion
  • Speaker : C Cannon (Boston,US)
  • Sponsored by MSD

Protecting patients at high risk of cardiac events and stroke: what are our options? Maria’s story.

Event : ESC Congress 2014

  • Session : Practical patient protection: celebrating the benefits of dabigatran 5 years on from RE-LY®
  • Speaker : C Cannon (Boston,US)
  • Sponsored by Boehringer Ingelheim

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are